DAWN Day One Biopharmaceuticals, Inc.
8-K Current Report
Filed: March 6, 2026
Health Care
Pharmaceutical PreparationsDay One Biopharmaceuticals, Inc. (DAWN) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 1.01 · Entry into a Material Definitive Agreement
- • Servier Pharmaceuticals (Parent) to acquire all DAWN shares at $21.50/share cash via tender offer — no financing condition
- • Tender offer launches within 15 business days of March 6, 2026; expires 20 business days after commencement unless extended
Item 8.01 · Other Events
- • DAWN entering merger agreement with unnamed "Parent" — acquisition via tender offer structure announced March 6, 2026
- • Tender offer (Schedule TO) not yet commenced; formal offer docs + DAWN's Schedule 14D-9 recommendation still pending SEC filing
Other Day One Biopharmaceuticals, Inc. 8-K Filings
Get deeper insights on Day One Biopharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.